JP2022511511A5 - - Google Patents

Info

Publication number
JP2022511511A5
JP2022511511A5 JP2021531950A JP2021531950A JP2022511511A5 JP 2022511511 A5 JP2022511511 A5 JP 2022511511A5 JP 2021531950 A JP2021531950 A JP 2021531950A JP 2021531950 A JP2021531950 A JP 2021531950A JP 2022511511 A5 JP2022511511 A5 JP 2022511511A5
Authority
JP
Japan
Prior art keywords
amount
present
booster vaccine
vaccine according
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511511A (ja
JP7605739B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063840 external-priority patent/WO2020117618A1/en
Publication of JP2022511511A publication Critical patent/JP2022511511A/ja
Publication of JP2022511511A5 publication Critical patent/JP2022511511A5/ja
Priority to JP2024126656A priority Critical patent/JP2024156862A/ja
Application granted granted Critical
Publication of JP7605739B2 publication Critical patent/JP7605739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531950A 2018-12-05 2019-11-29 百日咳ブースターワクチン Active JP7605739B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024126656A JP2024156862A (ja) 2018-12-05 2024-08-02 百日咳ブースターワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306621 2018-12-05
EP18306621.6 2018-12-05
PCT/US2019/063840 WO2020117618A1 (en) 2018-12-05 2019-11-29 Pertussis booster vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024126656A Division JP2024156862A (ja) 2018-12-05 2024-08-02 百日咳ブースターワクチン

Publications (3)

Publication Number Publication Date
JP2022511511A JP2022511511A (ja) 2022-01-31
JP2022511511A5 true JP2022511511A5 (https=) 2022-11-09
JP7605739B2 JP7605739B2 (ja) 2024-12-24

Family

ID=65628487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531950A Active JP7605739B2 (ja) 2018-12-05 2019-11-29 百日咳ブースターワクチン
JP2024126656A Pending JP2024156862A (ja) 2018-12-05 2024-08-02 百日咳ブースターワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024126656A Pending JP2024156862A (ja) 2018-12-05 2024-08-02 百日咳ブースターワクチン

Country Status (6)

Country Link
US (1) US20220054615A1 (https=)
EP (1) EP3890770A4 (https=)
JP (2) JP7605739B2 (https=)
CN (1) CN113395977A (https=)
TW (1) TWI877126B (https=)
WO (1) WO2020117618A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230072809A1 (en) * 2020-03-09 2023-03-09 Dynavax Technologies Corporation Active booster immunization against tetanus, diphtheria and pertussis
CN115554395A (zh) * 2022-10-12 2023-01-03 长春百克生物科技股份公司 一种百白破复合佐剂联合疫苗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX372965B (es) * 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
EP2822584A1 (en) * 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
AU2013301312A1 (en) * 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
JP6324961B2 (ja) * 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
US20180296663A1 (en) * 2015-06-17 2018-10-18 Curevac Ag Vaccine composition

Similar Documents

Publication Publication Date Title
JP4870895B2 (ja) ワクチン組成物
JP2014506916A5 (https=)
RU2008112289A (ru) Множественная вакцинация, включающая менингококки серогруппы с
JP2015028032A (ja) ワクチン
RU2009149359A (ru) Состав вакцин против менингита
PT1390066E (pt) Composição de vacina
JP2015509522A5 (https=)
RU2014140521A (ru) Адъювантные составы бустерных вакцин
CZ283910B6 (cs) Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku
RU2013136397A (ru) Комбинированная семивалентная вакцина
JP2015531389A5 (https=)
SG151253A1 (en) Combination vaccines with low dose of hib conjugate
JP2006527721A (ja) Ｂ型インフルエンザ菌糖ワクチン用ポリアニオン性ポリマーアジュバント
RU2015106745A (ru) Иммуногенные композиции
Mallet et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety
HU224126B1 (hu) Acelluláris pertussis vakcina diftéria- és tetanusz-toxoidokkal
Tejedor et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine
JP2022511511A5 (https=)
CN105007935A (zh) 用于保护免于白喉和/或破伤风的缀合物
Rodgers et al. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule
Wanlapakorn et al. Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age
Garçon et al. Development and evaluation of AS04, a novel and improved adjuvant system containing 3-o-desacyl-4′-monophosphoryl lipid a and aluminum salt
JP2022506347A (ja) 免疫原性組成物
RU2130778C1 (ru) Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
Pines et al. New acellular pertussis-containing paediatric combined vaccines